Clinical Trials Logo

Crigler-Najjar Syndrome clinical trials

View clinical trials related to Crigler-Najjar Syndrome.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03078881 Completed - Clinical trials for Crigler-Najjar Syndrome

Clinical Assessment Study in Crigler-Najjar Syndrome

LUSTRO
Start date: March 10, 2017
Phase:
Study type: Observational

This is a Pre-Phase 1 prospective, non-interventional clinical assessment study to evaluate Crigler-Najjar syndrome subjects requiring daily phototherapy, aged 1 year and older.

NCT ID: NCT02302690 Completed - Clinical trials for Crigler Najjar Syndrome

Immunity Against AAV in Crigler Najjar Patient

Start date: November 2014
Phase: N/A
Study type: Observational

The proposed research protocol aims at addressing these points by pre-screening CN patients for their AAV serology in link with their medical history and current medical status. A first objective is to assess the presence of neutralizing AAV antibodies in the serum of CN patients.

NCT ID: NCT02051049 Completed - Clinical trials for Urea Cycle Disorders

Long-term Safety Follow-up Study of Patients Having Received HepaStem (SAF001)

Start date: March 2013
Phase:
Study type: Observational

The purpose of this study is to assess the long-term safety follow-up of patients having been treated with HepaStem.

NCT ID: NCT01765283 Completed - Clinical trials for Urea Cycle Disorders

Safety Study of HepaStem for the Treatment of Urea Cycle Disorders (UCD) and Crigler-Najjar Syndrome (CN)

HEP001
Start date: March 2012
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and to appraise the efficacy of one cycle of Hepastem (Heterologous Human Adult Liver-derived Progenitor Cells, HHALPC) infusions in paediatric patients suffering from CN or UCD. The study duration: 12 months starting from the day of treatment: 6 months active surveillance and 6 months observation post-infusion.

NCT ID: NCT00461799 Completed - Clinical trials for Crigler-Najjar Syndrome

Orlistat Treatment of Crigler-Najjar Disease

Start date: September 2003
Phase: N/A
Study type: Interventional

The purpose of this study was to determine whether orlistat is effective in decreasing plasma unconjugated bilirubin levels in patients with Crigler-Najjar disease.